Article

A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2

2022-07-24

Abstract excerpt

<h4>Summary</h4> <h4>Background</h4> Molnupiravir was licensed for treating high-risk patients with COVID-19 based on data from unvaccinated adults. AGILE CST-2 ( NCT04746183 ) Phase II reports safety and virological efficacy of molnupiravir in vaccinated and unvaccinated individuals. <h4>Methods</h4> Adult out-patients with PCR-confirmed SARS-CoV-2 infection within five days of symptom onset were randomly assigne...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 173cb253-2eff-5411-b3ac-8d5976237d68
DOI: 10.1101/2022.07.20.22277797

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2DOI 10.1101/2022.07.20.22277797Read

Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trialSemantic proximity Read

Safety and Immunogenicity of an Inactivated Whole Virion SARS-CoV-2 Vaccine, TURKOVAC, in Healthy Adults: Interim Results from Randomised, Double-Blind, Placebo-Controlled Phase 1 and 2 TrialsSemantic proximity Read

Emulation of a target trial from observational data to compare effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for early treatment of non-hospitalized patients with COVID-19Semantic proximity Read

A Phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)Semantic proximity Read

Molnupiravir, an Oral Antiviral Treatment for COVID-19Semantic proximity Read

Molnupiravir Use and Severe Covid-19 Outcomes During the Omicron SurgeSemantic proximity Read

REGEN-COV Antibody Combination in Outpatients With COVID-19 – Phase 1/2 ResultsSemantic proximity Read

SARS-COV-2 nasopharyngeal viral load change in a multicenter randomized clinical trial comparing early therapies for COVID-19 in non-hospitalized adults with high risk of severe COVID-19 (the MONET TRIAL)Semantic proximity Read

Characterisation of SARS-CoV-2 genomic variations in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.Semantic proximity Read

Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variantsSemantic proximity Read

External validity of phase III trials on vaccines against SARS-CoV-2 to a middle-aged and elderly Western European populationSemantic proximity Read

The relationship between the number of COVID-19 vaccines and infection with Omicron ACE2 inhibition at 18-months post initial vaccination in an adult cohort of Canadian paramedicsSemantic proximity Read